Opendata, web and dolomites

HPE1

New high-performance excipients in pharmaceutical industry: an innovative solution for a more efficient and sustainable drug manufacturing process.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "HPE1" data sheet

The following table provides information about the project.

Coordinator
PHARMA73 SA 

Organization address
address: HERDADE DO BURRAZEIRO RIO DE MOINHOS
city: BORBA
postcode: 7150 390
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://www.pharma73.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PHARMA73 SA PT (BORBA) coordinator 50˙000.00

Map

 Project objective

'Pharma73 SA is a Portuguese start-up dedicated to the development, production and commercialization of a new generation of High Functionality Excipients (HFEs). Excipients are inactive ingredients used together with active ingredients to formulate drugs into finished dosage forms. Ranging from 15% to 95% of the total weight of a given drug, excipients are extremely important in terms of procurement, logistics, quality control and final batch release. Pharma73’s technology is based on the production of natural polymers, such as the Chitin Glucan Complex HPE1, obtained from fermentation processes whose unique properties enable their application in a multiplicity of pharmaceutical drugs for oral solid-dosage forms. Adding HPE1 to the final drug formulation will result in better yields and operational savings for the manufacturing industry, thanks to significant functional - physical and chemical properties of the new excipient. Pharma73’s ambition is to introduce a new raw material into the excipient markets, and bring the industry to a new level that better responds to efficiency and sustainability requirements of the drug manufacturing process. Furthermore the innovation related to the adoption of HPE1 will preserve the EU’s competitive advantage over drug manufacturing procedures, creating more job opportunities, and the long-term viability of a European-based pharmaceutical industry. Therefore the commercialization of a novel class of excipients like HPE1 aligns with the EU strategy “Europe 2020 – for a healthier EU”: 1) “Innovation can help make the healthcare sector more sustainable” 2) “the healthcare sector has an important role to play in improving skills and creating jobs as it employs 1 in 10 of the most qualified workers in the EU'. The SME instrument will allow Pharma 73 to complete their go-to-market strategy, by demonstrating HPE1 potential for specific drug formulation uses.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HPE1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HPE1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More